DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/3902430Curator's Comment: Description was created based on several sources, including http://en.pharmacodia.com/web/drug/1_7272.html
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3902430
Curator's Comment: Description was created based on several sources, including http://en.pharmacodia.com/web/drug/1_7272.html
Glyceryl 1-caprylate (Monooctanoin, Capmul 8210), a semisynthetic esterified glycerol, a cholesterol solvent, that has been used for the dissolution of retained cholesterol gallstones following cholecystectomy. Bile duct infusion of monooctanoin is associated with little toxicity, although potentially serious problems can result from absorption of the drug or tissue infiltration. Gastrointestinal side effects such as anorexia, nausea, vomiting, diarrhea, and abdominal pain have been reported most commonly. Complete gallstone dissolution has occurred in approximately 50-75 percent of patients receiving monooctanoin. Although mechanical stone removal is still considered to be the treatment of choice for retained gallstones, monooctanoin use appeared promising for stone dissolution in patients in whom mechanical removal has been unsuccessful or is impossible. Monoctanoin was approved by the U.S. Food and Drug Administration (FDA) on Oct 29, 1985. It was developed and marketed as Moctanin® by ETHITEK in US.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7380174
Curator's Comment: Thistle introduced monooctanoin therapy in 1980
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. | 1980 May |
|
In vitro dissolution of gallstones: comparison of monooctanoin, sodium dehydrocholate, heparin, and saline. | 1982 Feb |
|
Monooctanoin use for gallstone dissolution. | 1985 Oct |
|
Novel microemulsion-based gel formulation of tazarotene for therapy of acne. | 2016 Dec |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
2484
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
||
|
NCI_THESAURUS |
C78276
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3301678
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
C025343
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
Monoctanoin
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
84309
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
3364
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
SUB14594MIG
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
VFU0OU98LO
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
85241
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
DB06801
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | |||
|
30198
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY | RxNorm | ||
|
C66183
Created by
admin on Fri Dec 15 15:38:22 UTC 2023 , Edited by admin on Fri Dec 15 15:38:22 UTC 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY